Arbutus Biopharma (ABUS) Coverage Initiated at B. Riley

B. Riley initiated coverage on shares of Arbutus Biopharma (NASDAQ:ABUS) in a research note published on Friday morning, MarketBeat reports. The brokerage issued a buy rating and a $10.00 price objective on the biopharmaceutical company’s stock.

ABUS has been the topic of a number of other research reports. JMP Securities reaffirmed an outperform rating and set a $13.00 price objective (up previously from $12.00) on shares of Arbutus Biopharma in a research note on Wednesday, October 4th. Chardan Capital reaffirmed a buy rating on shares of Arbutus Biopharma in a research note on Wednesday, September 13th. Zacks Investment Research raised shares of Arbutus Biopharma from a sell rating to a hold rating in a research note on Tuesday, November 7th. Wedbush reaffirmed an outperform rating and set a $9.00 price objective on shares of Arbutus Biopharma in a research note on Wednesday, September 20th. Finally, BidaskClub raised shares of Arbutus Biopharma from a sell rating to a hold rating in a research note on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $12.50.

Shares of Arbutus Biopharma (ABUS) opened at $5.10 on Friday. The company has a market cap of $280.77, a P/E ratio of -1.02 and a beta of 1.07. Arbutus Biopharma has a one year low of $2.35 and a one year high of $8.25. The company has a debt-to-equity ratio of 0.08, a quick ratio of 11.03 and a current ratio of 11.03.

A number of institutional investors have recently added to or reduced their stakes in ABUS. Point72 Asset Management L.P. acquired a new stake in Arbutus Biopharma in the 3rd quarter valued at $1,393,000. Victory Capital Management Inc. acquired a new stake in Arbutus Biopharma in the 2nd quarter valued at $478,000. RTW Investments LP grew its stake in Arbutus Biopharma by 1.1% in the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after acquiring an additional 56,457 shares during the period. OxFORD Asset Management LLP grew its stake in Arbutus Biopharma by 49.2% in the 3rd quarter. OxFORD Asset Management LLP now owns 124,273 shares of the biopharmaceutical company’s stock valued at $778,000 after acquiring an additional 40,963 shares during the period. Finally, Vanguard Group Inc. grew its stake in Arbutus Biopharma by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 2,035 shares during the period. 59.97% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.com-unik.info/2018/01/09/arbutus-biopharma-abus-coverage-initiated-at-b-riley.html.

About Arbutus Biopharma

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit